Molecular and Cellular Biology, September 2001, p. 5925-5934, Vol. 21, No. 17
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.17.5925-5934.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati, College of Medicine, Cincinnati, Ohio 45267-0524
Received 28 February 2001/Returned for modification 26 April 2001/Accepted 8 June 2001
| |
ABSTRACT |
|---|
|
|
|---|
Notch genes encode a family of transmembrane proteins that are involved in many cellular processes such as differentiation, proliferation, and apoptosis. Although it is well established that all four Notch genes can act as oncogenes, the mechanism by which Notch proteins transform cells remains unknown. Previously, we have shown that transformation of RKE cells can be conditionally induced by hormone activation of Notchic-estrogen receptor (ER) chimeras. Using this inducible system, we show that Notchic activates transcription of the cyclin D1 gene with rapid kinetics. Transcriptional activation of cyclin D1 is independent from serum-derived growth factors and de novo synthesis of secondary transcriptional activators. Moreover, hormone activation of Notchic-ER proteins induces CDK2 activity in the absence of serum. Upregulation of cyclin D1 and activation of CDK2 by Notchic result in the promotion of S-phase entry. These data demonstrate the first evidence that Notchic proteins can directly regulate factors involved in cell cycle control and affect cellular proliferation. Furthermore, nontransforming Notchic proteins do not induce cyclin D1 expression, indicating that the mechanism of transformation involves cell cycle deregulation through constitutive expression of cyclin D1. Finally, we have identified a CSL [stands for CBF1, Su(H), and Lag-1] binding site within the human and rat cyclin D1 promoters, suggesting that Notchic proteins activate cyclin D1 transcription through a CSL-dependent pathway.
| |
INTRODUCTION |
|---|
|
|
|---|
There is now significant evidence that constitutively active alleles of all four Notch genes are involved in oncogenesis (2, 3, 14, 37, 42, 48). Furthermore, the importance of Notch mutations in the development of neoplastic diseases is underscored by studies of proviral-insertional mutagenesis. Infection of mice carrying a c-myc, E2A-PBX1, or erbB2 transgene with replication-competent retroviruses results in proviral integrations into the Notch1 locus, generating constitutively active alleles of Notch1 (9, 11, 15). In T-cell acute lymphoblastic leukemia, the chromosomal translocation t(7;9)(q34;q34.3) joins a portion of the T-cell receptor gene to the Notch1 gene, resulting in the aberrant expression of truncated Notch proteins (10). Although this is the only known genetic alteration involving the Notch1 locus in a human cancer, aberrant expression of Notch1, Notch2, and Notch3 has been observed in human cancers of different origins (1b, 6, 40, 56). Truncation of the extracellular sequences from Notch proteins results in constitutively active forms (termed Notchic) that are no longer tethered to the plasma membrane and localize primarily in the nucleus. Mutant forms of Notch1 and Notch2 analogous to those found in cells harboring a t(7;9)(q34;q34.3) translocation (Notch1ic and Notch2ic, respectively) transform an E1A-immortalized baby rat kidney cell line (RKE). These transformed cells form colonies in semisolid media and are tumorigenic in nude mice (3). The molecular mechanism by which Notch induces neoplastic transformation is not known. However, we have recently shown that both nuclear localization and transcriptional activation are requirements for Notchic-induced transformation (23, 43).
The current model for Notch signaling proposes that, following ligand binding, Notch is proteolytically processed, releasing the intracellular domain (Notchic) from the plasma membrane, which subsequently translocates to the nucleus. Once in the nucleus, Notchic interacts with CSL [acronym for CBF1, Su(H) and Lag-1] (22, 26, 29, 44, 49). It has been shown that CSL interacts with SMRT and CIR, which form complexes with histone deacetylases, suggesting a role for CSL in the repression of transcription (20, 25, 57). It has been proposed that Notchic binds to CSL, displacing the repressor complex and forming an activating complex, thereby converting CSL into an activator of transcription. It has been shown that Notch is able to interact with the histone acetylases PCAF and GCN5 by two-hybrid analysis, suggesting that a possible mechanism of induction of transcription of CSL target genes may involve chromatin remodeling (13, 19, 26, 30, 33).
A hallmark of neoplastic transformation is uncontrolled cellular proliferation. Deregulation of components of the cell cycle machinery that control the transition from the G1 to the S phase of the cell cycle is frequently involved in tumorigenesis. As a consequence, cells proliferate independently of extracellular queues. For example, tumor cells generally do not respond to growth-inhibitory signals induced by contact with neighboring cells and grow with a reduced dependence on serum in media (45, 52). Cyclin D1 has been shown to play a critical role in the control of the G1/S transition of the cell cycle. The level of expression of cyclin D1 is crucial for its function, and it is finely regulated. Cyclin D1 accumulation depends on the activation of transcription of the gene and is induced by many mitogenic signals. Cyclin D1 downregulation is, instead, mediated by a rapid degradation of the protein following ubiquitination (7, 8, 27, 46, 47). Overexpression of cyclin D1 has been shown to be associated with alterations of cell cycle kinetics and the acceleration of G1 phase, suggesting that cyclin D1 can directly induce cellular proliferation. Cells overexpressing cyclin D1 show a reduced dependence on serum and are, therefore, able to proliferate in lower concentrations of serum. However, cells overexpressing cyclin D1 grow in a reduced amount of serum with lower kinetics than those observed in cells in the presence of normal levels of serum, indicating that cyclin D1 is not able to fully compensate for the absence of serum-derived mitogens (36, 39, 58). Cyclin D1 alone is not able to induce complete cellular transformation. Expression of cyclin D1 in both primary and immortalized rodent cells did not result in the formation of foci but produced morphological transformation accompanied by acceleration of growth (18, 24). However, in several human tumors aberrant expression of cyclin D1 has been detected as a consequence of amplification or rearrangement of the gene and it has recently been suggested that cyclin D1 is likely to play an important role in transformation mediated by several other oncogenes, indicating a key role for cyclin D1 in tumorigenesis (16, 34, 41, 45, 50).
Previously, we demonstrated that Notchic proteins transform RKE cells and that transformation can be finely modulated by hormone activation of inducible Notchic-estrogen receptor (ER) chimeras (3, 23, 43). Here we use this inducible system in order to define the mechanism of transformation mediated by Notchic. We provide the first evidence that Notchic proteins can affect factors that play a critical role in cell cycle control. Following hormone induction, Notchic-ER chimeras activate cyclin D1 mRNA transcription, independently from serum-derived growth factors and de novo synthesis of secondary transcription factors. Furthermore, hormone induction of Notchic-ER chimeras leads to activation of CDK2. As a consequence, cells expressing Notchic display an increase in the number of cells undergoing DNA synthesis. Nontransforming Notchic mutant (mut) proteins fail to activate cyclin D1 transcription, indicating that Notchic proteins induce the transformation of RKE cells, in part, by deregulating the cell cycle through overexpression of cyclin D1. Finally, we demonstrate that CSL can bind to a CSL binding site identified in the cyclin D1 promoter, suggesting that activation of cyclin D1 transcription by Notchic proteins is CSL dependent.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Cells.
RKE and 293T cells were propagated in culture in
Dulbecco's modified Eagle's medium containing 10% fetal bovine serum
(FBS). Clonal RKE cell lines expressing the Notchic-ER
chimeras Nic, Nic with RAM deleted
(Nic
R), and Nic with amino acids 2105 to
2114 deleted (Nic
2105-2114) were previously described
(23, 43). In order to obtain the clonal RKE cell line
expressing RasV12 (RKE-Ras), RKE cells were transfected
with ZipNeo Kras4BV12 (kindly provided by C. J. Der)
using lipofectamine (Gibco-BRL). Isolated neomycin-resistant colonies
were selected, and cell lines were propagated in Dulbecco's modified
Eagle's medium supplemented with 10% FBS and 400 µg of neomycin per ml.
RT-PCR analysis.
Total RNA was extracted from confluent
cultures using Trizol Reagent (Life Technologies) according the
manufacturer's specifications. cDNA was synthesized from 2 µg of RNA
using Moloney murine leukemia virus reverse transcriptase (RT; Promega)
according to the manufacturer's protocol. One microliter of the
20-µl cDNA sample was used for PCR amplification. PCRs were performed
in a 50-µl mixture containing a 0.5 µM concentration of each
gene-specific primer, 1.5 mM MgCl2, 200 µM each
deoxynucleoside triphosphate, 1× PCR buffer (Hybaid), 0.2 U of DNA
polymerase (Hybaid), and 0.2 µCi of [
-32P]dCTP.
Sequences of primers used to specifically amplify endogenous rat mRNA
for cyclin D1, cyclin E, E2F-1, and Cdc25A are as described in the work
of Vigo et al. (51). The sequences of rat
-actin primers used for PCR are 5'-CGATATCGCTGCGCTCGTCGTCGAC-3' and
5'-GGCCAGGATAGAGCCACCAATCCAC-3'. In order to perform
semiquantitative PCR, we used cycling parameters that displayed a
linear range of amplification for each set of primers, determined by
amplifications of serial dilutions of cDNAs. Amplified PCR products
were separated on a 4% polyacrylamide gel in 1× Tris-acetate-EDTA
buffer. Quantification of the mRNA levels was performed using a Storm
PhosphorImager (Molecular Dynamics) and Image Quant analysis software.
Northern blot analysis.
Total RNA was isolated as described
for RT-PCR. Thirty micrograms of RNA per sample was electrophoresed on
a 1% agarose-6.5% formaldehyde gel and transferred overnight onto a
nylon filter. The hybridization was performed overnight at 65°C using
cyclin D1 and
-actin cDNAs radiolabeled with [
-32P]
dCTP using a randomly primed labeling kit (New England Biological Laboratories). The hybridization mixture contained 6× SSC (1× SSC is
0.15 µ NaCl plus 0.015 µ sodium citrate), 5× Denhardt's solution,
0.5% sodium dodecyl sulfate (SDS), and 0.1 mg of salmon sperm DNA per
ml. The blots were washed under high-stringency conditions, and
messages were visualized by autoradiography.
CDK2 assay. To measure CDK2 activity, clonal RKE cell lines were grown to confluence in 100-mm-diameter plates. Following serum starvation in medium containing 0.1% FBS for 48 h, cells were incubated overnight in medium containing either 0.1 or 10% FBS in the presence or absence of 1 µM 4-hydroxytamoxifen (OHT). Samples not treated with hormone received an equal volume of a 100% ethanol vehicle. Cells were lysed as described in the work of Matsushime et al. (35). CDK2 was immunoprecipitated from precleared lysates with an anti-CDK2 polyclonal antibody (kindly provided by K. Keyomarsi). The immunocomplexes were collected and assayed for kinase activity as previously described (4). Labeled proteins were separated by SDS-polyacrylamide gel electrophoresis and visualized by autoradiography. Quantitative analysis was performed as described for RT-PCR.
Thymidine incorporation. Clonal RKE cell lines were seeded in 24-well plates at 80% confluence. Following serum deprivation for 48 h, cells were induced in the presence or absence of 1 µM OHT in 0.1, 5, or 10% FBS for the times indicated in Fig. 4B. Measurement of [3H]thymidine incorporation into DNA was performed as previously described by incubating cells with 1 µCi of [3H]thymidine per ml for 2 h at 37°C (55).
EMSA. 293T cells were transiently transfected, using BES-modified calcium phosphate precipitation, with 5 µg of either green fluorescent protein (GFP) or a hemagglutinin (HA)-tagged CSL expression plasmid (CBF1-HA; kindly provided by P. D. Ling). (To be consistent with current literature, we refer to this protein as CSL throughout this paper.) After 48 h, cells were lysed and protein expression was assayed by Western immunoblotting as previously described (43), using an anti-CSL antibody (kindly provided by E. Bresnick) or an anti-HA tag antibody (HA-probe, Y-11; Santa Cruz). DNA binding reactions were performed according to the method of Lam and Bresnick (32) by incubating 20 µg of total cell extract with 60 fmol of 32P-labeled duplex oligonucleotides containing CSL binding sites. DNA-protein complexes were resolved on a 6.5% nondenaturing polyacrylamide gel in 0.75× Tris-acetate-EDTA buffer. The complete sequence of the 5'-3' strand of the oligonucleotides used for electrophoretic mobility shift assays (EMSA) is shown in Fig. 5A. The putative CSL binding site, GCTGAGAT, is in the center of the oligonucleotide and is flanked at both the 5' and 3' ends by 10 residues of a sequence derived from the human or rat cyclin D1 promoter. The mutant site used in our experiments, GCCTGCAG, was previously shown not to bind CSL (31). As a control for DNA binding experiments, we also used an oligonucleotide that contains three copies of a high-affinity CSL binding sequence, GTGGGAA, spanned by 10 random residues (JK3X). The complete sequence of the wild-type (wt) JK3X oligonucleotide is 5'-CGTGGGAAATTTGACTTCGTGGGAAATTTGACTTCGTGGGAA-3', and that of the mut JK3X is 5'-CTCTGGAAATTTGACTTCTCTGGAAATTTGACTTCTCTGGAA-3', where the CSL binding site is underlined and the mutated residues are shown in boldface.
| |
RESULTS |
|---|
|
|
|---|
Hormone-dependent activation of Notchic-ER chimeras induces cyclin D1 mRNA transcription. Recently we created inducible Notchic chimeric proteins by fusing the intracellular portion of Notch to the estrogen binding domain of the human ER. We reported that the activation of Notchic-ER chimeras can be finely modulated by treatment with OHT and that hormone activation of Notchic-ER proteins induces transformation of RKE cells in a dose-dependent manner (43). Transformed cells are characterized by uncontrolled cellular proliferation. An important checkpoint of cellular proliferation is the transition from the G1 to the S phase of the cell cycle. A fundamental mechanism to control the G1/S transition is the regulation of expression of cell cycle machinery components. In order to determine if Notchic-induced transformation involves transcriptional activation of genes encoding factors known to play a role in this transition, we analyzed the mRNA levels of the cyclin D1, cyclin E, Cdc25A, and E2F-1 genes by RT-PCR.
Total RNA was extracted from clonal RKE cell lines expressing either Notchic-ER chimeras (ER-Nic and Nic-ER) or the estrogen binding domain (ER) alone (43). Following serum deprivation for 48 h, cells were treated for 5 h with or without 1 µM OHT in medium containing either a low (0.1%) or a full (10%) concentration of serum. Hormone activation of Notchic-ER chimeras induced the accumulation of cyclin D1 mRNA in a low concentration of serum (Fig. 1A). In cells expressing the ER-Nic chimera, the level of cyclin D1 mRNA detected in samples treated in 0.1% serum plus 1 µM OHT was approximately sevenfold higher than the level detected in a low concentration of serum in the absence of OHT. Under the same experimental conditions, cells expressing the Nic-ER chimeric protein displayed a four-fold increase in the induction of cyclin D1 transcription. The level of cyclin D1 induced by serum alone was approximately threefold higher than the basal level detected in 0.1% serum in the absence of OHT. However, the induction of cyclin D1 transcription by serum in the presence of OHT was twofold higher than the induction by serum alone (Fig. 1). In control cells expressing ER alone, cyclin D1 mRNA was detectable only upon stimulation with 10% serum. OHT had no effect on cyclin D1 mRNA expression (Fig. 1A). Northern blot analysis of total RNA extracted from samples treated under the experimental conditions described above confirmed the induction of cyclin D1 transcription by hormone-activated Notchic-ER chimeras, validating the results observed by RT-PCR (Fig. 1B). We did not observe an increase in mRNA levels for cyclin E, E2F-1, and Cdc25A upon hormone activation of Notchic-ER (Fig. 1A), indicating that hormone-activated Notchic-ER chimeras specifically induced transcription of cyclin D1. Furthermore, our data show that the activation of cyclin D1 induced by Notchic-ER proteins is independent of the induction by other serum growth factors.
|
Induction of cyclin D1 expression by Notchic-ER
proteins is direct.
It has been reported that the induction of
cyclin D1 transcription by serum typically requires from 3 to 4 h
(5, 21, 53, 54). In RKE cells, induction of cyclin D1 mRNA
by serum is detectable in approximately 5 h (Fig.
2A). In contrast, cyclin D1 mRNA induced
by hormone activation of Notchic-ER proteins can be
detected in 1 h (Fig. 2). The rapid induction of cyclin D1 mRNA
suggests that Notchic can activate cyclin D1 transcription
through a direct mechanism.
|
Nontransforming Notchic proteins fail to activate
cyclin D1 transcription.
We have previously described mutations
that affect the ability of Notchic proteins to induce the
transformation of RKE cells (23). In order to determine if
the transforming ability of Notchic proteins depends on
their ability to activate cyclin D1 transcription, we extracted total
RNA from clonal RKE cell lines expressing Notchic and two
different Notchic mut proteins and analyzed cyclin D1 mRNA
by RT-PCR. Clonal RKE cells expressing Notchic displayed a
level of cyclin D1 mRNA sevenfold higher than the level detected for
the parental RKE cell line. In contrast, the level of cyclin D1 mRNA
detected in the RKE clonal line expressing Nic
R was only
threefold higher than the level in RKE cells (Fig.
3). Nic
R lacks the primary
binding domain for CSL (RAM domain). We have previously shown that
Nic
R displays a weaker ability to form foci than that of
Notchic, likely due to a diminished ability to interact
with CSL and activate transcription (23). In contrast,
Nic
2105-2114 failed to induce cyclin D1 mRNA
expression. The level of cyclin D1 mRNA detected in cells expressing
Nic
2105-2114 was similar to the basal level detected in
RKE cells (Fig. 3). Nic
2105-2114 has a 10-amino-acid
deletion that abolishes its ability to transform cells and to activate
transcription from a reporter construct containing CSL high-affinity
binding sites, although it is still able to bind CSL (23).
As described for Notchic-ER chimeras (Fig. 1A),
transcriptional activation of cyclin D1 by Notchic was
specific, since all clonal RKE cell lines express similar constitutive
levels of cyclin E, E2F-1, and Cdc25A mRNA (Fig. 3). For comparison, we
determined the level of cyclin D1 mRNA in RKE cells transformed by
RasV12 (RKE-Ras). RKE-Ras expressed cyclin D1 to a level
20-fold higher than the level observed in RKE cells. Here we show that
Notchic proteins that are incapable of activating cyclin D1
transcription fail to transform cells, suggesting that the mechanism of
transformation mediated by Notchic requires the induction
of cyclin D1 expression.
|
Hormone activation of Notchic-ER chimeras induces CDK2
activity and promotes entry into the S phase of the cell cycle.
We
demonstrated that Notchic activates cyclin D1
transcription. We wanted to determine if Notchic is able to
affect components of the cell cycle machinery that act downstream of
cyclin D1 and, specifically, if it is able to induce cells to progress
into the cell cycle. We measured CDK2 activity, which is induced in
late G1 and commits cells to entry into the S phase.
Following serum deprivation for 48 h, cells were treated in 0.1 or
10% serum in the presence or absence of 1 µM OHT for 12 h. CDK2
was immunoprecipitated from precleared lysates with an anti-CDK2
antibody. Immunocomplexes were assayed for kinase activity using
histone H1 as an exogenous substrate for CDK2. Hormone activation of
both ER-Nic and Nic-ER chimeras resulted in
induction of CDK2 activity in the absence of other serum growth factors
(0.1% FBS plus OHT) (Fig. 4A). The level
of CDK2 activity detected in samples incubated in low-concentration serum in the presence of OHT was approximately threefold higher than
the basal level (Fig. 4A). In contrast, treatment of cells expressing
ER with OHT in 0.1% serum did not result in CDK2 activation above the
basal level (Fig. 4A). Treatment with serum resulted in CDK2 activity
approximately threefold above background in all the RKE cell lines.
However, no significant difference was detected in samples incubated in
the presence or absence of OHT in 10% serum (Fig. 4A). These results
indicate that Notchic proteins can play a critical role in
the regulation of the cell cycle through induction of CDK2 activity,
independently of other serum-derived mitogenic signals.
|
CSL binds to the cyclin D1 promoter.
In order to define the
mechanism of induction of cyclin D1 mRNA mediated by
Notchic, we searched for possible regulatory elements
related to the Notch signal transduction pathway in the cyclin D1
promoter. We identified a putative CSL binding site located at position
513 in the human cyclin D1 promoter (GenBank accession no. Z29078) (17) and at position
767 in the rat cyclin D1 promoter
(GenBank accession no. AF148946) (28). A schematic
representation of the human and rat cyclin D1 promoter with binding
sites for transcription factors as described in the literature is shown in Fig. 5A. The sequence of the putative
CSL binding site is GCTGAGAT; this sequence is different
from the consensus sequence for the high-affinity CSL binding site
(GTGGGAA) previously described. However, a similar sequence,
GCTGAGAA, has been identified in the human
-globin locus
control region, which has been demonstrated to be an authentic CSL
binding site (31).
|
|
| |
DISCUSSION |
|---|
|
|
|---|
Hormone-induced Notchic-ER chimeras activate key components of the cell cycle machinery that regulate the G1/S transition. A hallmark of neoplastic transformation is the deregulation of cellular proliferation through the disruption of key components of the cell cycle machinery that control the G1/S transition of the cell cycle (45, 52). Activation of transcription is an important mechanism in the regulation of several of these key factors. By examining the mRNA level of several genes that encode factors known to regulate the transition from the G1 to the S phase, we determined that hormone-activated Notchic-ER chimeras specifically induce cyclin D1 transcription. Our data demonstrate that hormone activation of Notchic-ER induces cyclin D1 transcription with rapid kinetics and independently of de novo synthesis of secondary transcription factors. Moreover, serum-derived mitogens are not required for Notchic to induce cyclin D1 mRNA expression. However, induction of cyclin D1 mRNA by serum was approximately twofold higher in the presence of OHT than in serum alone in the absence of hormone (Fig. 1 and 2B), indicating that Notchic can act synergistically with serum factors to induce cyclin D1 transcription. Indeed, the regulation of cyclin D1 transcription is complex and tightly modulated. Binding sites for numerous transcription factors have been identified in the promoter of the cyclin D1 gene, and several signal transduction pathways are involved in the activation of cyclin D1 mRNA transcription (1a, 2a, 34a, 34c). For example, transcriptional activation of cyclin D1 through mitogenic signals primarily involves the Ras-dependent pathway through MEK1-ERK and the AP1 binding site present in the cyclin D1 promoter (1, 1a, 4a, 27a).
Cyclins control cell cycle progression by regulating the activity of cyclin-dependent kinases (CDK). Association of cyclins with specific CDK partners activates the catalytic activities of these kinases, which then phosphorylate target proteins, such as Rb, to regulate the cell cycle. Specifically, the cyclin E-CDK2 complex is active in late G1 and is required to commit cells to S-phase entry by phosphorylating Rb and thereby, causing the release of E2F (27, 27b, 34b, 36a). We demonstrate that hormone-activated Notchic-ER chimeras induce CDK2 activity in the absence of serum. These data suggest that Notchic can stimulate cells to progress into the cell cycle through the induction of cyclin D1 transcription and activation of CDK2 activity, providing the first evidence that Notchic can affect key components of the cell cycle machinery and indicating a direct involvement of Notch proteins in the regulation of cellular proliferation. By analyzing the incorporation of [3H]thymidine, we determined that the activation of Notchic-ER increases the number of cells that initiate DNA synthesis both in full (10%) and in reduced (5%) concentrations of serum, indicating that Notchic is able to promote cells to enter into the S phase of the cell cycle. However, hormone activation of Notchic -ER proteins did not significantly increase DNA synthesis in 0.1% serum, suggesting that induction of cyclin D1 expression and activation of CDK2 by Notchic in RKE cells are not sufficient to induce proliferation. RKE cells are immortalized by the adenoviral oncoprotein E1A. E1A is thought to immortalize cells by inactivating Rb and thereby causing the release of E2F, which in turn induces genes involved in the G1-to-S transition (38). However, cells expressing ER alone were quiescent in the absence of serum, indicating that E1A, in our experimental system, is not sufficient to override normal cell cycle controls and induce a transition from G1 to S. Furthermore, in 10% serum RKE cells density arrest, indicating that, although they are immortal and express E1A, RKE cells retain tight regulation of the cell cycle. Activation of Notchic leads to a constitutive level of cyclin D1 and CDK2 activity and thereby contributes to the disruption of cell cycle control, resulting in the failure of RKE cells to withdraw from the cell cycle due to contact inhibition. However, the requirement for serum in order to promote S-phase entry by Notchic suggests that constitutive activation of cyclin D1 and CDK2 (in addition to E1A) is not sufficient to transform cells and that other factors in serum are likely to contribute to oncogenic transformation by Notchic. Interestingly, cells derived from mammary carcinomas induced in Notch4ic transgenic mice require MEK and P13K activity, as indicated by the failure of these cells to form colonies in semisolid media in the presence of the inhibitors PD098059 and LY294002, respectively (12). These results might provide a clue to the identities of the missing components required in our study. We therefore propose that to drive RKE cells into S phase and for these to become transformed, it is necessary to have cooperation among Notchic, E1A, and the Ras pathways.The mechanism of transformation induced by Notchic
proteins involves the activation of cyclin D1 transcription through a
CSL-dependent pathway.
CSL is a sequence-specific DNA-binding
transcriptional regulator and is one of the principal effectors of
Notch signaling. CSL acts in the nuclei of cells as a transcriptional
repressor, inhibiting the transcription of genes containing CSL binding
sites. It has been proposed that, following ligand activation,
Notchic translocates to the nucleus and associates with
CSL, converting CSL to a transcriptional activator by displacing the
corepressor complex containing SMRT, HDAC1, NcoR or CIR and HDAC2.
Therefore, the formation of the Notchic-CSL complex results
in the induction of transcription of CSL target genes
(35a). We have identified a CSL binding site in the cyclin
D1 promoter and showed that CSL specifically binds to this sequence.
Previously, we reported that transformation mediated by
Notchic proteins requires transcriptional activation
(23). Here we show that a 10-amino-acid deletion in
Nic
2105-2114 results in the complete loss of the
transcriptional activation of cyclin D1 by Notchic.
Nic
2105-2114 is nontransforming, and although it is
able to bind CSL as well as Notchic, it fails to activate
transcription from a reporter construct containing eight copies of a
CSL consensus sequence (23). Therefore, it is likely that
Nic
2105-2114 is missing a domain responsible for
transcriptional activation. In contrast, deletion of the RAM domain in
Notchic (Nic
R) results in a decreased
ability of Nic
R to induce cyclin D1 transcription
compared to that of Notchic proteins. Nic
R
displays a weaker ability to form foci and to activate CSL-dependent transcription than that of Notchic (23). In
glutathione S-transferase pull-down experiments, deletion of
the RAM domain is sufficient to abolish the binding of
Notchic to CSL. However, in cells transformed by versions
of Notchic
R we find that small fractions of Notch and
CSL exist in a stable complex (S. Jeffries and A. J. Capobianco,
unpublished data). Therefore, the reduced level of cyclin D1
transcription is consistent with a reduced level of binding between
Notchic and CSL. Our results suggest that, in order to
induce cyclin D1 expression, Notchic proteins must be able
to bind to CSL and to activate gene transcription. We have previously
shown that Notchic-ER chimeras are able to activate
transcription of a reporter construct containing eight CSL binding
sites only in the presence of OHT. However, Notchic-ER
chimeras bind to CSL both in the presence and in the absence of OHT
(43). These data suggest that, in the absence of OHT, Notchic-ER and CSL form a complex that is not
transcriptionally active. Our hypothesis is that OHT may induce a
conformational change in Notchic that favors the binding to
the complex of factors required for activation of transcription.
R to transform cells
is related to its diminished ability to induce cyclin D1 mRNA
expression. Therefore, we propose that the oncogenic mechanism driven
by Notchic involves the disruption of the normal cell cycle
control and that the induction of cyclin D1 and the activation of CDK2
play a critical role in the acquisition of the transformed state
induced by Notchic proteins.
| |
ACKNOWLEDGMENTS |
|---|
We thank members of the Capobianco laboratory for support and technical assistance. We thank David Robbins and Yolanda Sanchez for insightful comments on our work. We are grateful to C. J. Der (University of North Carolina), K. Keyomarsy (M. D. Anderson Cancer Center), P. D. Ling (Baylor College of Medicine), E. Bresnick (University of Winsconsin), and J. A. Diehl (University of Nebraska) for kindly providing reagents used in this study.
This work was funded in part by grants from the American Cancer Society (RPG LBC-99465 to A. J. Capobianco) and the National Cancer Institute (ROI CA 83736 to A. J. Capobianco).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Molecular Genetics, University of Cincinnati, College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0524. Phone: (513) 558-3664. Fax: (513) 558-8474. E-mail: tony.capobianco{at}uc.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Aktas, H., H. Cai, and G. M. Cooper. 1997. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol. Cell. Biol. 17:3850-3857[Abstract]. |
| 1a. |
Albanese, C.,
J. Johnson,
G. Watanabe,
N. Eklund,
D. Vu,
A. Arnold, and R. G. Pestell.
1995.
Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions.
J. Biol. Chem.
270:23589-23597 |
| 1b. | Aster, J., W. Pear, R. Hasserjian, H. Erba, F. Davi, B. Luo, M. Scott, D. Baltimore, and J. Sklar. 1994. Functional analysis of the TAN-1 gene, a human homolog of Drosophila notch. Cold Spring Harbor Symp. Quant. Biol. 59:125-136[Medline]. |
| 2. | Bellavia, D., A. F. Campese, E. Alesse, A. Vacca, M. P. Felli, A. Balestri, A. Stoppacciaro, C. Tiveron, L. Tatangelo, M. Giovarelli, C. Gaetano, L. Ruco, E. S. Hoffman, A. C. Hayday, U. Lendahl, L. Frati, A. Gulino, and I. Screpanti. 2000. Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J. 19:3337-3348[CrossRef][Medline]. |
| 2a. | Bromberg, J. F., M. H. Wrzeszczynska, G. Devgan, Y. Zhao, R. G. Pestell, C. Albanese, and J. E. Darnell, Jr. 1999. Stat3 as an oncogene. Cell 98:295-303[CrossRef][Medline]. (Erratum, 99:239.) |
| 3. | Capobianco, A. J., P. Zagouras, C. M. Blaumueller, S. Artavanis-Tsakonas, and J. M. Bishop. 1997. Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2. Mol. Cell. Biol. 17:6265-6273[Abstract]. |
| 4. | Cheng, M., P. Olivier, J. A. Diehl, M. Fero, M. F. Roussel, J. M. Roberts, and C. J. Sherr. 1999. The p21 (Cip1) and p27(Kip1) CDK `inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18:1571-1583[CrossRef][Medline]. |
| 4a. |
Cheng, M.,
V. Sexl,
C. J. Sherr, and M. F. Roussel.
1998.
Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1).
Proc. Natl. Acad. Sci. USA
95:1091-1096 |
| 5. | Daksis, J. I., R. Y. Lu, L. M. Facchini, W. W. Marhin, and L. J. Penn. 1994. Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene 9:3635-3645[Medline]. |
| 6. | Daniel, B., A. Rangarajan, G. Mukherjee, E. Vallikad, and S. Krishna. 1997. The link between integration and expression of human papillomavirus type 16 genomes and cellular changes in the evolution of cervical intraepithelial neoplastic lesions. J. Gen. Virol. 78:1095-1101[Abstract]. |
| 7. |
Diehl, J. A.,
M. Cheng,
M. F. Roussel, and C. J. Sherr.
1998.
Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization.
Genes Dev.
12:3499-3511 |
| 8. |
Diehl, J. A.,
F. Zindy, and C. J. Sherr.
1977.
Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway.
Genes Dev.
11:957-972 |
| 9. | Dievart, A., N. Beaulieu, and P. Jolicoeur. 1999. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene 18:5973-5981[CrossRef][Medline]. |
| 10. | Ellisen, L. W., J. Bird, D. C. West, A. L. Soreng, T. C. Reynolds, S. D. Smith, and J. Sklar. 1991. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66:649-661[CrossRef][Medline]. |
| 11. |
Feldman, B. J.,
T. Hampton, and M. L. Cleary.
2000.
A carboxy-terminal deletion mutant of Notch1 accelerates lymphoid oncogenesis in E2A-PBX1 transgenic mice.
Blood
96:1906-1913 |
| 12. | Fitzgerald, K., A. Harrington, and P. Leder. 2000. Ras pathway signals are required for notch-mediated oncogenesis. Oncogene 19:4191-4198[CrossRef][Medline]. |
| 13. | Fortini, M. E., and S. Artavanis-Tsakonas. 1994. The suppressor of hairless protein participates in notch receptor signaling. Cell 79:273-282[CrossRef][Medline]. |
| 14. |
Gallahan, D.,
C. Kozak, and R. Callahan.
1987.
A new common integration region (int-3) for mouse mammary tumor virus on mouse chromosome 17.
J. Virol.
61:218-220 |
| 15. |
Girard, L.,
Z. Hanna,
N. Beaulieu,
C. D. Hoemann,
C. Simard,
C. A. Kozak, and P. Jolicoeur.
1996.
Frequent provirus insertional mutagenesis of Notch1 in thymomas of MMTVD/myc transgenic mice suggests a collaboration of c-myc and Notch1 for oncogenesis.
Genes Dev.
10:1930-1944 |
| 16. | Hall, M., and G. Peters. 1996. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 68:67-108[Medline]. |
| 17. | Herber, B., M. Truss, M. Beato, and R. Muller. 1994. Inducible regulatory elements in the human cyclin D1 promoter. Oncogene 9:1295-1304[Medline]. (Erratum, 9:2105-2107.) |
| 18. |
Hinds, P. W.,
S. F. Dowdy,
E. N. Eaton,
A. Arnold, and R. A. Weinberg.
1994.
Function of a human cyclin gene as an oncogene.
Proc. Natl. Acad. Sci. USA
91:709-713 |
| 19. | Hsieh, J. J., T. Henkel, P. Salmon, E. Robey, M. G. Peterson, and S. D. Hayward. 1996. Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Mol. Cell. Biol. 16:952-959[Abstract]. |
| 20. |
Hsieh, J. J.,
S. Zhou,
L. Chen,
D. B. Young, and S. D. Hayward.
1999.
CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex.
Proc. Natl. Acad. Sci. USA
96:23-28 |
| 21. | Ishii, T., M. Shimizu, Y. Kanayama, S. Nakada, H. Nojima, and K. Oda. 1993. Differential activation of cyclin and cyclin-dependent kinase genes by adenovirus E1A12S cDNA product. Exp. Cell Res. 208:407-414[CrossRef][Medline]. |
| 22. | Jarriault, S., C. Brou, F. Logeat, E. H. Schroeter, R. Kopan, and A. Israel. 1995. Signalling downstream of activated mammalian Notch. Nature 377:355-358[CrossRef][Medline]. |
| 23. |
Jeffries, S., and A. J. Capobianco.
2000.
Neoplastic transformation by Notch requires nuclear localization.
Mol. Cell. Biol.
20:3928-3941 |
| 24. | Jiang, W., S. M. Kahn, P. Zhou, Y. J. Zhang, A. M. Cacace, A. S. Infante, S. Doi, R. M. Santella, and I. B. Weinstein. 1993. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 8:3447-3457[Medline]. |
| 25. |
Kao, H. Y.,
P. Ordentlich,
N. Koyano-Nakagawa,
Z. Tang,
M. Downes,
C. R. Kintner,
R. M. Evans, and T. Kadesch.
1998.
A histone deacetylase corepressor complex regulates the Notch signal transduction pathway.
Genes Dev.
12:2269-2277 |
| 26. | Kato, H., Y. Taniguchi, H. Kurooka, S. Minoguchi, T. Sakai, S. Nomura-Okazaki, K. Tamura, and T. Honjo. 1997. Involvement of RBP-J in biological functions of mouse Notch1 and its derivatives. Development 124:4133-4141[Abstract]. |
| 27. | Kato, J. 1999. Induction of S phase by G1 regulatory factors. Front Biosci. 4:D787-D792[Medline]. |
| 27a. | Kerkhoff, E., and U. R. Rapp. 1997. Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1. Mol. Cell. Biol. 17:2576-2586[Abstract]. |
| 27b. | Keyomarsi, K., and T. W. Herliczek. 1997. The role of cyclin E in cell proliferation, development and cancer. Prog. Cell Cycle Res. 3:171-191[Medline]. |
| 28. |
Kitazawa, S.,
R. Kitazawa, and S. Maeda.
1999.
Transcriptional regulation of rat cyclin D1 gene by CpG methylation status in promoter region.
J. Biol. Chem.
274:28787-28793 |
| 29. |
Kopan, R.,
E. H. Schroeter,
H. Weintraub, and J. S. Nye.
1996.
Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain.
Proc. Natl. Acad. Sci. USA
93:1683-1688 |
| 30. |
Kurooka, H., and T. Honjo.
2000.
Functional interaction between the mouse notch1 intracellular region and histone acetyltransferases PCAF and GCN5.
J. Biol. Chem.
275:17211-17220 |
| 31. |
Lam, L. T., and E. H. Bresnick.
1998.
Identity of the beta-globin locus control region binding protein HS2NF5 as the mammalian homolog of the notch-regulated transcription factor suppressor of hairless.
J. Biol. Chem.
273:24223-24231 |
| 32. |
Lam, L. T., and E. H. Bresnick.
1996.
A novel DNA-binding protein, HS2NF5, interacts with a functionally important sequence of the human beta-globin locus control region.
J. Biol. Chem.
271:32421-32429 |
| 33. |
Lecourtois, M., and F. Schweisguth.
1995.
The neurogenic suppressor of hairless DNA-binding protein mediates the transcriptional activation of the enhancer of split complex genes triggered by Notch signaling.
Genes Dev.
9:2598-2608 |
| 34. |
Lee, R. J.,
C. Albanese,
M. Fu,
M. D'Amico,
B. Lin,
G. Watanabe,
G. K. Haines III,
P. M. Siegel,
M. C. Hung,
Y. Yarden,
J. M. Horowitz,
W. J. Muller, and R. G. Pestell.
2000.
Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway.
Mol. Cell. Biol.
20:672-683 |
| 34a. |
Lee, R. J.,
C. Albanese,
R. J. Stenger,
G. Watanabe,
G. Inghirami,
G. K. Haines III,
M. Webster,
W. J. Muller,
J. S. Brugge,
R. J. Davis, and R. G. Pestell.
1999.
pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells.
J. Biol. Chem.
274:7341-7350 |
| 34b. |
Lukas, J.,
T. Herzinger,
K. Hansen,
M. C. Moroni,
D. Resnitzky,
K. Helin,
S. I. Reed, and J. Bartek.
1997.
Cyclin E-induced S phase without activation of the pRb/E2F pathway.
Genes Dev.
11:1479-1492 |
| 34c. | Matsumura, I., T. Kitamura, H. Wakao, H. Tanaka, K. Hashimoto, C. Albanese, J. Downward, R. G. Pestell, and Y. Kanakura. 1999. Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J. 18:1367-1377[CrossRef][Medline]. |
| 35. |
Matsushime, H.,
D. E. Quelle,
S. A. Shurtleff,
M. Shibuya,
C. J. Sherr, and J. Y. Kato.
1994.
D-type cyclin-dependent kinase activity in mammalian cells.
Mol. Cell. Biol.
14:2066-2076 |
| 35a. | Mumm, J. S., and R. Kopan. 2000. Notch signaling: from the outside in. Dev. Biol. 228:151-165[CrossRef][Medline]. |
| 36. |
Musgrove, E. A.,
C. S. Lee,
M. F. Buckley, and R. L. Sutherland.
1994.
Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle.
Proc. Natl. Acad. Sci. USA
91:8022-8026 |
| 36a. | Ohtsubo, M., A. M. Theodoras, J. Schumacher, J. M. Roberts, and M. Pagano. 1995. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol. Cell. Biol. 15:2612-2624[Abstract]. |
| 37. |
Pear, W. S.,
J. C. Aster,
M. L. Scott,
R. P. Hasserjian,
B. Soffer,
J. Sklar, and D. Baltimore.
1996.
Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles.
J. Exp. Med.
183:2283-2291 |
| 38. | Peeper, D. S., and A. Zantema. 1993. Adenovirus-E1A proteins transform cells by sequestering regulatory proteins. Mol. Biol. Rep. 17:197-207[CrossRef][Medline]. |
| 39. |
Quelle, D. E.,
R. A. Ashmun,
S. A. Shurtleff,
J. Y. Kato,
D. Bar-Sagi,
M. F. Roussel, and C. J. Sherr.
1993.
Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts.
Genes Dev.
7:1559-1571 |
| 40. | Rae, F. K., S. A. Stephenson, D. L. Nicol, and J. A. Clements. 2000. Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display. Int. J. Cancer 88:726-732[CrossRef][Medline]. |
| 41. |
Rimerman, R. A.,
A. Gellert-Randleman, and J. A. Diehl.
2000.
Wnt1 and MEK1 cooperate to promote cyclin D1 accumulation and cellular transformation.
J. Biol. Chem.
275:14736-14742 |
| 42. | Rohn, J. L., A. S. Lauring, M. L. Linenberger, and J. Overbaugh. 1996. Transduction of Notch2 in feline leukemia virus-induced thymic lymphoma. J. Virol. 70:8071-8080[Abstract]. |
| 43. | Ronchini, C., and A. J. Capobianco. 2000. Notch(ic)-ER chimeras display hormone-dependent transformation, nuclear accumulation, phosphorylation and CBF1 activation. Oncogene 19:3914-3924[CrossRef][Medline]. |
| 44. | Schroeter, E. H., J. A. Kisslinger, and R. Kopan. 1998. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 393:382-386[CrossRef][Medline]. |
| 45. |
Sherr, C. J.
1996.
Cancer cell cycles.
Science
274:1672-1677 |
| 46. | Sherr, C. J. 1994. G1 phase progression: cycling on cue. Cell 79:551-555[CrossRef][Medline]. |
| 47. | Sherr, C. J. 1995. Mammalian G1 cyclins and cell cycle progression. Proc. Assoc. Am. Physicians 107:181-186[Medline]. |
| 48. | Soriano, J. V., H. Uyttendaele, J. Kitajewski, and R. Montesano. 2000. Expression of an activated Notch4(int-3) oncoprotein disrupts morphogenesis and induces an invasive phenotype in mammary epithelial cells in vitro. Int. J. Cancer 86:652-659[CrossRef][Medline]. |
| 49. | Struhl, G., and A. Adachi. 1998. Nuclear access and action of notch in vivo. Cell 93:649-660[CrossRef][Medline]. |
| 50. | Tetsu, O., and F. McCormick. 1999. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-426[CrossRef][Medline]. |
| 51. |
Vigo, E.,
H. Muller,
E. Prosperini,
G. Hateboer,
P. Cartwright,
M. C. Moroni, and K. Helin.
1999.
CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase.
Mol. Cell. Biol.
19:6379-6395 |
| 52. | Weinberg, R. A. 1995. The retinoblastoma protein and cell cycle control. Cell 81:323-330[CrossRef][Medline]. |
| 53. | Winston, J. T., and W. J. Pledger. 1993. Growth factor regulation of cyclin D1 mRNA expression through protein synthesis-dependent and -independent mechanisms. Mol. Biol. Cell 4:1133-1144[Abstract]. |
| 54. |
Won, K. A.,
Y. Xiong,
D. Beach, and M. Z. Gilman.
1992.
Growth-regulated expression of D-type cyclin genes in human diploid fibroblasts.
Proc. Natl. Acad. Sci. USA
89:9910-9914 |
| 55. |
Yamamoto, M.,
M. Acevedo-Duncan,
C. E. Chalfant,
N. A. Patel,
J. E. Watson, and D. R. Cooper.
2000.
Acute glucose-induced downregulation of PKC-betaII accelerates cultured VSMC proliferation.
Am. J. Physiol. Cell Physiol.
279:C587-C595 |
| 56. |
Zagouras, P.,
S. Stifani,
C. M. Blaumueller,
M. L. Carcangiu, and S. Artavanis-Tsakonas.
1995.
Alterations in Notch signaling in neoplastic lesions of the human cervix.
Proc. Natl. Acad. Sci. USA
92:6414-6418 |
| 57. |
Zhou, S.,
M. Fujimuro,
J. J. Hsieh,
L. Chen,
A. Miyamoto,
G. Weinmaster, and S. D. Hayward.
2000.
SKIP, a CBF1-associated protein, interacts with the ankyrin repeat domain of Notch1C to facilitate Notch1C function.
Mol. Cell. Biol.
20:2400-2410 |
| 58. | Zwijsen, R. M., R. Klompmaker, E. B. Wientjens, P. M. Kristel, B. van der Burg, and R. J. Michalides. 1996. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit. Mol. Cell. Biol. 16:2554-2560[Abstract]. |
This article has been cited by other articles: